Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...146147148149150151152153154155156...859860»
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal:  Sclerostin and Cardiovascular Disease. (Pubmed Central) -  Jul 25, 2023   
    One study also suggested that sclerostin lowering increases coronary artery calcification. Triangulation of evidence from different sources provides some suggestion that sclerostin lowering increases MI risk, supporting the need for CVD risk assessment when considering treatment with romosozumab.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2325;    
    SHERLOCK is a phase II, single arm, open-label, multicentre, clinical trial collaboration between the Thoracic Oncology Group of Australasia and the National Health and Medical Research Council Clinical Trials Centre, University of Sydney...A total of 52 participants will be recruited to account for dropout. The SHERLOCK trial commenced recruitment in August 2022 and the study is currently ongoing.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN) (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2232;    
    Further analysis of a possible temporal association between ICI use and sotorasib toxicity is needed. The combination of denosumab and PD-1 inhibitors demonstrated anti-tumor activity in the advanced KRAS-mutated NSCLC with a good safety profile, which warrants further investigation.Table 1 Treatment-Related Adverse Events in the Overall PopulationAEsn (%)Any AEs11 (55)Specific AEs-Tooth-related AEs*4 (20)Arthralgia2 (10)Fatigue1 (5)Hypothyroidism2 (10)ALT/AST elevation2 (10)Creatinine elevation2 (10)Serious AEs0Deaths due to AEs0AEs leading to discontinuation1 (5)
  • ||||||||||  Leveraging NLP to Identify Biomarker-Eligible Patients (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2053;    
    These results were obtained from NLP analysis of attending physician notes and did not require manual searching for copies of actual genomic reports. This approach can potentially expedite identification of non-small cell lung cancer patients for complex clinical trials.
  • ||||||||||  elesclomol (STA-4783) / Madrigal Pharma
    Targeting ATP7A by Elesclomol-Copper Derived Endoplasmic Reticulum Stress to Mediate Cuproptosis in KRAS-G12 Mutant LUAD (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1946;    
    Elesclomol transports exogenous copper ions into LUAD cells, activates endoplasmic reticulum stress by inducing the accumulation of misfolded proteins, and upregulates the expression of E3 ligase RNF207, which induces ubiquitination and degradation of ATP7A and further increases the retention of copper ions in cells, ultimately mediating cuproptosis of KRASG12 mutant LUAD cells. In summary, targeting copper metabolism may break through the bottleneck of KRASG12 mutant LUAD treatment.
  • ||||||||||  Ameile (aumolertinib) / Jiangsu Hansoh Pharma, EQRx
    A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1714;    
    In our case, aumolertinib monotherapy brought more surprises for advanced lung adenocarcinoma patients with multiple metastases in addition to brain metastasis,which could take into account both efficacy and safety. The rapid effect brought by EGFR-TKI can delay the timing of local treatment for brain and bone metastases, thereby enabling patients to have a higher quality of life.
  • ||||||||||  Krazati (adagrasib) / Mirati, ARS-1620 / Kura Oncology, J&J, Araxes Pharma, Lumakras (sotorasib) / Amgen
    Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1213;    
    Combination of KRAS G12C inhibitor (AMG-510, MRTX849, and ARS-1620) and mTOR inhibitor (Everolimus) showed synergism in both adenocarcinoma and squamous cell carcinoma cell lines. The targetable somatic variant G12C in KARS should be explored in squamous cell carcinoma as well as in adenocarcinoma.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Osteoporotic Vertebral Fractures in Non-small Cell Lung Cancer : A Cracking Connection (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1194;    
    Diagnosis and management of OVF in this setting requires a multidisciplinary approach. Identifying risk factors such as corticosteroid exposure and malnutrition should be part of a comprehensive prevention policy to mitigate osteoporosis complications.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC (405B) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_989;    
    Additionally, the total protein of H1975-OR treated with BC3448 or Panitumumab for 2 days was subsequently subjected for Sally Sue Simple Western analysis. BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a promising agent for Osimertinib-resistant NSCLC.
  • ||||||||||  SB202190 / Amgen
    Journal:  Photobiomodulation inhibits the expression of chondroitin sulfate proteoglycans after spinal cord injury via the Sox9 pathway. (Pubmed Central) -  Jul 25, 2023   
    Furthermore, we found that the increased levels of p-Smad3, p-P38 and p-Erk in inflammatory astrocytes were reduced after photobiomodulation treatment and after delivery of inhibitors including FR 180204, (E)-SIS3, and SB 202190...In summary, our findings show that photobiomodulation modulates the expression of chondroitin sulfate proteoglycans, and versican is one of the key target molecules of photobiomodulation. MAPK/Sox9 and Smad3/Sox9 pathways may play a role in the effects of photobiomodulation on chondroitin sulfate proteoglycan accumulation after spinal cord injury.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
    Retrospective data, Review, Journal:  Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis. (Pubmed Central) -  Jul 24, 2023   
    In terms of effectiveness, PCSK9 inhibitors reduced the risk of major adverse cardiovascular events(MACE) (OR=0.89, 95% Cl: 0.83-0.95, P=0.0009), but did not significantly reduce the risk of cardiovascular death (OR=0.95, 95% Cl: 0.84-1.07, P=0.38) or all-cause death (OR=0.93, 95% Cl: 0.85-1.03, P=0.18); In terms of safety, PCSK9 did not increase the risk of treatment-emergent adverse events (TEAE)(OR=0.98, 95% Cl: 0.94-1.02, P=0.28). PCSK9 inhibitors can significantly reduce the risk of MACE in patients with high cardiovascular risk, which is well tolerated, but the impact on the risk of death is unclear.
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Journal, Real-world evidence, Real-world:  Prescription patterns of granulocyte colony-stimulating factors in patients with breast cancer: A real-world study. (Pubmed Central) -  Jul 21, 2023   
    Our study results show that G-CSFs are used for primary prophylaxis in a small percentage of patients with breast cancer and the duration of short-acting G-CSF use is relatively short. Considering the significant clinical and economic impact of FN, it is hoped that the prescription patterns of G-CSFs observed can provide an important reference for future clinical practice and reimbursement policy.
  • ||||||||||  Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
    Treatment of NMOSD and MOGAD: an update (Gold) -  Jul 21, 2023 - Abstract #MSMilan2023MSMilan_1877;    
    Registered therapies are available for NMOSD relapse prevention; prospective studies for MOGAD relapse prevention are beginning. Optimization of acute care for NMOSD and MOGAD attacks remains an unmet need.
  • ||||||||||  Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation For Multiple Sclerosis (Gold) -  Jul 21, 2023 - Abstract #MSMilan2023MSMilan_1091;    
    In the BAT arm, participants are treated with any of the following: cladribine, natalizumab, alemtuzumab, ocrelizumab, ofatumumab, or rituximab... BEAT-MS is a large prospective multi-center randomized clinical trial comparing AHSCT to contemporary high efficacy DMTs, with the goal of determining whether AHSCT is a clinically effective, safe, and cost-effective treatment option for highly active RMS.
  • ||||||||||  Relapse and Non-Relapse Hospitalizations in Neuromyelitis Optica Spectrum Disorders (Gold) -  Jul 21, 2023 - Abstract #MSMilan2023MSMilan_343;    
    NMOSD results in lengthy hospitalizations both for relapses and non-relapses frequently complicated by infections. While disease modifying therapies may prevent relapses, further investigation is needed for optimal prevention of non-relapse hospitalizations.
  • ||||||||||  Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
    Matching-Adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-Term Effectiveness (Gold) -  Jul 21, 2023 - Abstract #MSMilan2023MSMilan_337;    
    Additionally, treatment with inebilizumab yields better results for expected life years and quality adjusted life years compared to either satralizumab or eculizumab. Relative efficacy and discontinuation were the key drivers of the results.
  • ||||||||||  Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen
    Association of Cytokine Proteins with Disease Activity in NMOSD Participants Receiving Inebilizumab Treatment (Gold) -  Jul 21, 2023 - Abstract #MSMilan2023MSMilan_336;    
    P2/3
    Relative efficacy and discontinuation were the key drivers of the results. Pro-inflammatory cytokines were elevated in a subset of N-MOmentum participants at baseline including IL-6, IL-17a, and IFN inducible chemokines.** Longitudinal analysis revealed a correlation with MRI findings through the duration of N-MOmentum.** Regardless of baseline cytokine levels, improvement in disease activity was observed with inebilizumab treatment.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Review, Journal:  Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib. (Pubmed Central) -  Jul 21, 2023   
    Genetic mutations, drug tolerance, and other factors may influence CDK4/6 resistance mechanisms. Currently, the resistance mechanisms differences of the three drugs remain largely unknown, and there are differences in the resistance mechanisms among them, necessitating further exploration and research.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Gilotrif (afatinib) / Boehringer Ingelheim, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Enrollment open, Trial primary completion date, Tumor cell:  Pilot Trial for Treatment of Recurrent Glioblastoma (clinicaltrials.gov) -  Jul 21, 2023   
    P1,  N=10, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> May 2023 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Jul 2027
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, omecamtiv mecarbil (AMG 423) / Amgen, Servier
    PN216. The Ejection Fraction is Low, and Stress Levels Are High: Newer Therapies for HFrEF and Implications for the Anesthesiologist (South: 310/311/312) -  Jul 20, 2023 - Abstract #ASA2023ASA_2141;    
    Session Learning Objective 2: List the salient indications for and implications of newer implantable devices for the management of HFrEF. Session Learning Objective 3: Apply the the latest updates from national and international consensus guidelines by describing contrasting recommendations concerning the perioperative management of heart failure patients.
  • ||||||||||  plerixafor / Generic mfg.
    Trial primary completion date:  Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) (clinicaltrials.gov) -  Jul 20, 2023   
    P1/2,  N=60, Active, not recruiting, 
    Session Learning Objective 3: Apply the the latest updates from national and international consensus guidelines by describing contrasting recommendations concerning the perioperative management of heart failure patients. Trial primary completion date: Dec 2025 --> Jul 2023
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
    Trial completion date:  AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) -  Jul 20, 2023   
    P1b,  N=23, Active, not recruiting, 
    Trial primary completion date: Dec 2025 --> Jul 2023 Trial completion date: Aug 2025 --> Jan 2026
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Trial primary completion date:  Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL (clinicaltrials.gov) -  Jul 20, 2023   
    P1,  N=10, Active, not recruiting, 
    Trial completion date: Aug 2025 --> Jan 2026 Trial completion date: Feb 2024 --> Mar 2025 | Trial primary completion date: Jul 2023 --> Mar 2023